6-[4-(Bromomethyl)phenyl]-5-phenylnicotinonitrile | 790659-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-[4-(Bromomethyl)phenyl]-5-phenylnicotinonitrile
• 英文别名: 6-[4-(bromomethyl)phenyl]-5-phenylpyridine-3-carbonitrile
• CAS: 790659-93-7
• 化学式: C₁₉H₁₃BrN₂
• 分子量: 349.23
• InChiKey: CBLZUVFOUSNWOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(5-piperidin-4-yl-1H-pyrazol-3-yl)pyridine 、 6-[4-(Bromomethyl)phenyl]-5-phenylnicotinonitrile 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 以57%的产率得到5-phenyl-6-(4-((4-(5-(pyridin-2-yl)-1H-pyrazol-3-yl)piperidin-1-yl)methyl)phenyl)nicotinonitrile
  参考文献：
  名称：

  Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors

  摘要：

  This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic pro. le of an optimized inhibitor that has low clearance and long half-life in dogs. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.040
• 作为产物：
  描述：

  6-(4-methylphenyl)-5-phenylnicotinonitrile 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 氘代氯仿 为溶剂， 反应 20.0h， 以93%的产率得到6-[4-(Bromomethyl)phenyl]-5-phenylnicotinonitrile
  参考文献：
  名称：

  Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors

  摘要：

  This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic pro. le of an optimized inhibitor that has low clearance and long half-life in dogs. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.040

文献信息

• Inhibitors of akt activity
  申请人：Duggan E Mark

  公开号：US20060270673A1

  公开（公告）日：2006-11-30

  The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及一种含有取代吡啶基团的化合物，该化合物抑制Akt，一种丝氨酸/苏氨酸蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物以及使用本发明化合物治疗癌症的方法。
• Inhibitors of Akt activity
  申请人：Merck & Co., Inc.

  公开号：US07414055B2

  公开（公告）日：2008-08-19

  The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及一种含有取代吡啶基团的化合物，该化合物抑制Akt蛋白激酶的活性。本发明进一步涉及包含本发明化合物的化疗组合物以及治疗癌症的方法，包括给予本发明化合物的治疗。
• INHIBITORS OF AKT ACTIVITY
  申请人：Merck & Co., Inc.

  公开号：EP1631548A2

  公开（公告）日：2006-03-08
• EP1631548A4
  申请人：——

  公开号：EP1631548A4

  公开（公告）日：2007-10-31
• US7414055B2
  申请人：——

  公开号：US7414055B2

  公开（公告）日：2008-08-19